- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34 result(s) found for: CD40.
Displaying page 1 of 2.
EudraCT Number: 2014-003733-25 | Sponsor Protocol Number: CHUBX2013/27 | Start Date*: 2014-12-03 |
Sponsor Name:CHU de BORDEAUX | ||
Full Title: Pilot Study related to the effect of clopidogrel on plasmatic soluble CD40 ligand during systemic lupus erythematous | ||
Medical condition: systemic lupus erythematous | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000713-11 | Sponsor Protocol Number: CV149-208 | Start Date*: 2007-07-20 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) on Inflammatory and Platelet Activation Markers i... | |||||||||||||
Medical condition: Biomarkers of inflammation and platelet activation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000097-35 | Sponsor Protocol Number: CCFZ533X2204 | Start Date*: 2015-09-02 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moder... | |||||||||||||
Medical condition: Acquired myasthenia gravis (MG) is an autoimmune disease that leads to fluctuating muscle weakness and fatigue. In the most common cases, muscle weakness is caused by circulating antibodies that bi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002835-32 | Sponsor Protocol Number: BP29392 | Start Date*: 2015-01-26 | |||||||||||
Sponsor Name:Roche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION PHASE IB STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONIST) IN COMBINATION WITH MP... | |||||||||||||
Medical condition: Locally Advanced and/ or Metastatic Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003235-31 | Sponsor Protocol Number: Prof. Franz Weidinger | Start Date*: 2005-01-31 |
Sponsor Name:Div. of Cardiology, Innsbruck Medical University | ||
Full Title: Effect of pravastatin or fluvastatin and add-on valsartan on inflammatory markers and peripheral endothelial function in patients with acute coronary syndrome | ||
Medical condition: Acute coronary syndrome; patients with NSTEMI | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-004888-22 | Sponsor Protocol Number: CHCD122A2103 | Start Date*: 2008-03-27 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed... | ||
Medical condition: Advanced non Hodgkin's or Hodgkin's lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) DE (Completed) FR (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001368-22 | Sponsor Protocol Number: DG-041-CV-008 | Start Date*: 2006-06-01 |
Sponsor Name:deCODE genetics ehf. | ||
Full Title: A randomized, double blind, placebo controlled phase II evaluation of the pharmacokinetics, pharmacodynamics and safety of DG-041 in PAD patients | ||
Medical condition: Peripheral arterial disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IS (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-010832-17 | Sponsor Protocol Number: RIVIERA/09 | Start Date*: 2009-08-21 | |||||||||||
Sponsor Name:Dr. Francisco Bosa Ojeda | |||||||||||||
Full Title: Ensayo clínico, randomizado, doble ciego y controlado con placebo de la ivabradina en pacientes con síndrome coronario agudo: Efectos de la ivabradina en la reducción del estrés oxidativo y de mar... | |||||||||||||
Medical condition: Síndrome Coronario Agudo | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018491-24 | Sponsor Protocol Number: 31295 | Start Date*: 2010-07-15 | |||||||||||
Sponsor Name:Vrije Universiteit Medical Center | |||||||||||||
Full Title: Effect of aminobisphosphonates and statins on circulating Vy9Vd2-T cells | |||||||||||||
Medical condition: patients with malignant bone metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022248-19 | Sponsor Protocol Number: 114825 | Start Date*: 2011-01-25 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination ... | |||||||||||||
Medical condition: Evaluation of persistence of immune responses following immunisation of healthy elderly subjects (60-69 and ≥70 years) against Herpes Zoster (HZ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) NL (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003866-14 | Sponsor Protocol Number: APX005M-002 | Start Date*: 2019-02-28 | ||||||||||||||||
Sponsor Name:Apexigen, Inc. | ||||||||||||||||||
Full Title: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastati... | ||||||||||||||||||
Medical condition: Non-small Cell Lung Cancer and Metastatic Melanoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-005788-34 | Sponsor Protocol Number: NL79578.100.21 | Start Date*: 2022-03-31 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect | ||
Medical condition: Atrial septal defect or patent foramen ovale indicated for percutaneous closure with an occluder device. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001508-12 | Sponsor Protocol Number: CVAY736X2208 | Start Date*: 2018-11-02 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess pharmacodynamics, pharmacokinetics, safety, tolerability and preliminary clinical efficacy of VA... | |||||||||||||
Medical condition: Systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000925-36 | Sponsor Protocol Number: CCFZ533X2201 | Start Date*: 2015-11-26 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 12-month randomized, multiple dose, open-label, study evaluating safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of an anti-CD40 monoclonal antibody, CFZ533, in combi... | |||||||||||||
Medical condition: acute rejection of renal transplant in de novo adult renal transplant patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004400-30 | Sponsor Protocol Number: 204926 | Start Date*: 2016-02-24 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase IIIB, open, long term extension study to evaluate the persistence of immune responses and the safety of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine 1437173A, at Months 108 and 12... | ||||||||||||||||||||||||||||
Medical condition: Herpes Zoster (HZ) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SE (Completed) DE (Completed) CZ (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004476-35 | Sponsor Protocol Number: CCFZ533B2201 | Start Date*: 2019-08-19 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial to assess the safety and efficacy of multiple CFZ533 doses administered subcutaneously in two distinct populations o... | |||||||||||||
Medical condition: Sjögren syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) HU (Completed) GB (GB - no longer in EU/EEA) NL (Completed) GR (Completed) FR (Completed) DE (Completed) SE (Completed) AT (Completed) SI (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020219-35 | Sponsor Protocol Number: | Start Date*: 2011-07-18 |
Sponsor Name:Royal Brompton & Harefield NHS Foundation Trust | ||
Full Title: Evaluating the benefit of additional platelet inhibition in acute coronary syndrome patients with high platelet reactivity undergoing PCI | ||
Medical condition: Cardiovascular disease - Acute coronary syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003864-30 | Sponsor Protocol Number: APX005M-010 | Start Date*: 2019-02-08 | |||||||||||
Sponsor Name:Apexigen, Inc. | |||||||||||||
Full Title: A Study to Evaluate the Safety and efficacy of the CD40 Agonistic Antibody APX005M in Adults with Immunotherapy Naive Metastatic Melanoma | |||||||||||||
Medical condition: Unresectable or metastatic melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003230-93 | Sponsor Protocol Number: CCFZ533X2202 | Start Date*: 2018-05-09 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, placebo-controlled, patient and investigator blinded study investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of multiple doses of CFZ533 in patients wi... | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000311-87 | Sponsor Protocol Number: FFC-0001 | Start Date*: 2012-04-23 | |||||||||||
Sponsor Name:Fundación Fernández-Cruz | |||||||||||||
Full Title: A long-term, randomized, open-labeled, parallel-group trial to compare the effects of liraglutide and sulphonilurea both in combination with metformin on clinical, endothelial and image markers of ... | |||||||||||||
Medical condition: type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
